A comparison of the effects of invasive mechanic ventilation/surfactant therapy and non-invasive nasal-continuous positive airway pressure in preterm newborns

J Matern Fetal Neonatal Med. 2018 Dec;31(24):3225-3231. doi: 10.1080/14767058.2017.1367380. Epub 2017 Aug 31.

Abstract

Aims: This study compared the early-term outcomes of mechanical ventilation (MV)/surfactant treatment with nasal-continuous positive airway pressure (nCPAP) in preterm infants with respiratory distress syndrome (RDS).

Materials and methods: Data from newborns born between ≥24 and ≤32 weeks of gestation, hospitalized at our newborn intensive care unit, and diagnosed with RDS between January 2009 and February 2012 were analyzed.

Results: Of 193 newborns with RDS who were enrolled in the study, 113 were treated with nCPAP and 80 with MV at a level of 57.5% of nCPAP. Within the study group, 46.3% of the infants were female. The mean gestation of the continuous positive airway pressure (CPAP) group was 29.07 ± 1.99 weeks; that of the MV group was 28.61 ± 2.01 weeks. The birth weight was 1321.1 ± 325.4 g and 1240.3 ± 366.1 g; however, the difference between the two groups was not significant. MV was not required in 54.9% of the patients with nCPAP treatment. Bronchopulmonary dysplasia (BPD) developed in 20 (18.7%) patients in the nCPAP group and 18 (24.4%) patients in the MV group; the difference was not significant (p = .351). Between 2009 and 2012, nCPAP was used at a rate of 33.9, 70.8, 68.4, and 69%. The risk factors for developing BPD were low gestation week, duration of intubation, and proven sepsis (p = .0001, p = .004, and p = .011, respectively).

Conclusions: Early nCPAP treatment in preterm infants (≤32 weeks of gestation) decreases both the need for MV and the use of surfactant, but without a significant effect on BPD development. (No. 2016/324).

Keywords: Bronchopulmonary dysplasia; mechanical ventilation; nasal-continuous positive airway pressure; preterm.

Publication types

  • Comparative Study

MeSH terms

  • Bronchopulmonary Dysplasia / etiology*
  • Continuous Positive Airway Pressure / adverse effects*
  • Continuous Positive Airway Pressure / statistics & numerical data
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Pulmonary Surfactants / therapeutic use
  • Respiratory Distress Syndrome, Newborn / therapy*
  • Retrospective Studies

Substances

  • Pulmonary Surfactants

Supplementary concepts

  • Respiratory Distress Syndrome In Premature Infants